Copyright
©The Author(s) 2016.
World J Hepatol. Jan 28, 2016; 8(3): 139-147
Published online Jan 28, 2016. doi: 10.4254/wjh.v8.i3.139
Published online Jan 28, 2016. doi: 10.4254/wjh.v8.i3.139
Table 2 Overview on clinical studies using the NS5B inhibitor sofosbovir
| Study | Patient population | Therapy | Duration (wk) | SVR | Comments |
| ION-1 | First-line therapy | SOF + LDV | 12 | 99% | |
| SOF + LDV + R | 12 | 97% | |||
| SOF + LDV | 24 | 98% | |||
| SOF + LDV + R | 24 | 99% | |||
| ION-2 | Re-therapy | SOF + LDV | 12 | 94% | 86% cirrhotic |
| SOF + LDV + R | 12 | 96% | 82% cirrhotic | ||
| SOF + LDV | 24 | 99% | 100% cirrhotic | ||
| SOF + LDV + R | 24 | 99% | 86% cirrhotic | ||
| ION-3 | First-line therapy | SOF + LDV | 8 | 94% | Only non-cirrhotic |
| SOF + LDV + R | 8 | 93% | Only non-cirrhotic | ||
| SOF + LDV | 12 | 95% | Only non-cirrhotic |
- Citation: Zopf S, Kremer AE, Neurath MF, Siebler J. Advances in hepatitis C therapy: What is the current state - what come’s next? World J Hepatol 2016; 8(3): 139-147
- URL: https://www.wjgnet.com/1948-5182/full/v8/i3/139.htm
- DOI: https://dx.doi.org/10.4254/wjh.v8.i3.139